A Study of Endocrine Function in the Treatment of Benign Prostatic Hypertrophy with Megestrol Acetate

  title={A Study of Endocrine Function in the Treatment of Benign Prostatic Hypertrophy with Megestrol Acetate},
  author={Paul E. Lebech and Erik L{\o}ssl Nordentoft},
  journal={Acta Obstetricia et Gynecologica Scandinavica},
According to Flocks (1964) at least 65 per cent of the American male population over 60 years old suffer from Benign Prostatic Hypertrophy (BPH) and, in a selected group of Danish male patients, Lund (1959) found symptoms of BPH in 43 per cent over the age of 65. This will serve to explain the large number of reports published on the use of drug therapy, a great many of which deal with the administration of hormones. Such an approach has been widely advocated on the basis that BPH, to a certain… 
Endocrine treatment of benign prostatic hypertrophy: current concepts.
The combination of an antiandrogenic and antiestrogenic effect is theoretically promising in the treatment of human BPH and a good hormonal treatment that will be both scientifically sound, and clinically safe and effective seems feasible in the near future.
The response of the benign hypertrophied prostate to endocrine therapy
Histological evidence of benign prostatic hypertrophy (BPH) can be found in the prostates of almost all men as they exceed the age of 40. The true incidence is difficult to determine as most
Conservative treatment of benign prostatic hyperplasia.
A study was carried out in 30 male patients with benign prostate hyperplasia to assess the effectiveness of treatment with a progestational agent, gestonorone caproate (200 mg), given intramucularly
Benign prostatic hypertrophy treated with a gestagen. A double-blind clinical trial with randomized allocation.
  • T. Hald, A. From
  • Medicine
    Scandinavian journal of urology and nephrology
  • 1972
It is concluded that double-blind techniques are indispensable in the evaluation of hormone treatment of benign prostatic hypertrophy since the symptoms may fluctuate spontaneously over long periods of time and a pronounced placebo effe:t is to be expected.
Megestrol acetate in treatment of benign prostatic hypertrophy.
Since the urodynamic evidence does indicate a possibility of a positive effect, it appears reasonable to investigate further using a different protocol - perhaps a higher dosage and/or a more controlled test population.
Medical treatment of benign prostatic hypertrophy
Benign prostatic hypertrophy results in clinical symptoms in 65% of males over 60 years of age and there is frequently coincidental cardiac, renal, or pulmonary pathology, adding to the risk of the surgical procedure.
Therapy with progestational agents in advanced benign prostatic hypertrophy.
Of eight patients responding favorably to treatment, residual urine, symptoms of prostatism, and renal function remained stable for an average follow-up of 13 months following discontinuation of therapy.
Treatment of benign prostatic hypertrophy with medrogestone
Twenty‐four patients with established benign prostaue hypertrophy (BPH) uiere treated at random in a double‐blind manner with one of two drug schedules: medrogestone [or 24 weeks followed by placebo
Megestrol acetate: clinical experience.
Megestrol acetate can be considered as an effective medical alternative to surgery for endometrial hyperplasia or benign prostatic hypertrophy, and has the advantage of stimulating appetite and weight gain, a benefit in cancer patients.
Effect of megestrol acetate on uroflow rates in patients with benign prostatic hypertrophy: double-blind study.
Patients with benign prostatic hypertrophy and decreased maximum and mean urine flow rates were randomly assigned to megestrol or placebo therapy andMegestrol-treated patients showed statistically significant increases in maximum flow rate at fourteen, sixteen, and twenty weeks after therapy, and statisticallysignificant increases in mean flow rate over the placebo patients at ten, twelve, fourteen, andTwenty weeks.


Fifth World Congress for Fertility and Starup
  • Acta Endocr. (Kbh.) 53,
  • 1966
Cancer Institute, (Washington) I , 1963. Sterility
  • Progr. Hormone Res. zz
  • 1955
Les Cystopathies Endocrines (Th6se) Foulon, (Paris), I 952
  • J. Urol
  • 1937
Acta Endocr . ( Kbh . ) 193 , 121 , 1965 . 1967